Northern Trust’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-668,872
| Closed | -$23M | – | 4464 |
|
|
2020
Q3 | $23M | Buy |
668,872
+93,766
| +16% | +$2M | 0.01% | 1518 |
|
|
2020
Q2 | $9.61M | Buy |
575,106
+28,080
| +5% | +$477K | ﹤0.01% | 2122 |
|
|
2020
Q1 | $7.89M | Buy |
547,026
+3,895
| +0.7% | +$99.6K | ﹤0.01% | 2026 |
|
|
2019
Q4 | $18.2M | Sell |
543,131
-13,649
| -2% | -$382K | ﹤0.01% | 1795 |
|
|
2019
Q3 | $11.7M | Buy |
556,780
+24,706
| +5% | +$504K | ﹤0.01% | 2046 |
|
|
2019
Q2 | $11.1M | Buy |
532,074
+4,726
| +0.9% | +$97.3K | ﹤0.01% | 2087 |
|
|
2019
Q1 | $11.8M | Buy |
527,348
+1,556
| +0.3% | +$36.6K | ﹤0.01% | 2043 |
|
|
2018
Q4 | $12.6M | Sell |
525,792
-1,978
| -0.4% | -$51.2K | ﹤0.01% | 1916 |
|
|
2018
Q3 | $14.4M | Buy |
527,770
+9,189
| +2% | +$260K | ﹤0.01% | 2025 |
|
|
2018
Q2 | $13.9M | Buy |
518,581
+108,034
| +26% | +$3.31M | ﹤0.01% | 2042 |
|
|
2018
Q1 | $13.1M | Buy |
410,547
+32,723
| +9% | +$1.15M | ﹤0.01% | 1988 |
|
|
2017
Q4 | $14.3M | Sell |
377,824
-40,375
| -10% | -$1.3M | ﹤0.01% | 1954 |
|
|
2017
Q3 | $10.4M | Buy |
418,199
+26,209
| +7% | +$565K | ﹤0.01% | 2182 |
|
|
2017
Q2 | $8.06M | Buy |
391,990
+77,744
| +25% | +$1.48M | ﹤0.01% | 2310 |
|
|
2017
Q1 | $6.83M | Buy |
314,246
+25,873
| +9% | +$531K | ﹤0.01% | 2367 |
|
|
2016
Q4 | $5.9M | Buy |
288,373
+8,724
| +3% | +$178K | ﹤0.01% | 2448 |
|
|
2016
Q3 | $4.2M | Buy |
279,649
+141,051
| +102% | +$1.9M | ﹤0.01% | 2625 |
|
|
2016
Q2 | $1.5M | Buy |
138,598
+19,169
| +16% | +$260K | ﹤0.01% | 3184 |
|
|
2016
Q1 | $1.62M | Buy |
119,429
+1,261
| +1% | +$19.7K | ﹤0.01% | 3085 |
|
|
2015
Q4 | $2.18M | Buy |
118,168
+86,210
| +270% | +$1.59M | ﹤0.01% | 3013 |
|
|
2015
Q3 | $809K | Buy |
+31,958
| New | +$747K | ﹤0.01% | 3370 |
|
Northern Trust's AIMT Position: Q4 2020 in Review
Northern Trust sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 668,872 shares — an estimated $23M sold.
Northern Trust first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $23M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Northern Trust reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Northern Trust sold 668,872 Aimmune Therapeutics shares in Q4 2020, an estimated $23M.
- Northern Trust first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Northern Trust's Aimmune Therapeutics position peaked at $23M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Northern Trust's 13F filing for Q4 2020, filed 11 Feb 2021.